Liandi Chen
10 Papers
3 Citations
Liandi Chen is an academic researcher. The author has contributed to research in topics: Cancer research & Immunology. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
Xiaoniu Miao,Luo Yi,Xi Huang,Suki M. Y. Lee,Zhijun Yuan,Yongzhou Tang,Liandi Chen,Chao Wang,Wenchao Jiang,Wei Gao,Xuedong Song,Yao Yan,Tuling Pang,Yuefeng Zou,Weihui Fu,Liping Wan,Javier Gilbert-Jaramillo,Michael L. Knight,Tiong Kit Tan,Pramila Rijal,Alain Townsend,Joanne Sun,Xiaolin Liu,William James,Andy Tsun,Yingda Xu +25 more
TL;DR: 89C8-ACE2 shows exceptional performance in vitro, inhibiting the interaction of recombinant S1 to ACE2 and transduction of ACE2-overexpressing cells by S-pseudotyped lentivirus with IC50s substantially below 100 pM, and with potency approximately 100-fold greater thanACE2-Fc itself.
3
Abstract 5674: Anti-CCR8-based bispecific antibodies engineered to preferentially eliminate tumor-infiltrating regulatory T cells: leaving effectors unharmed
Tianhang Zhai,Shuang Dai,Weifeng Huang,Yuanhong Chen,Shaogang Peng,Liandi Chen,Chao Wang,Zhiyuan Li,Andy Tsun +8 more
TL;DR: Zhai et al. as mentioned in this paper proposed an anti-CCR8/TIGIT bispecific antibody (PM1024) that preferentially eliminates CCR8 and TIGIT double positive cells over single positive cells.
1
Abstract 6115: Development of functionally differentiating anti-CD73 antibodies for cancer therapy
Zhen-Qiang Zhang,Yunli Jia,Xiaoniu Miao,Weifeng Huang,Chao Wang,Z F Yuan,Wenchao Jiang,Zhiyuan Li,Liandi Chen,Andy Tsun +9 more
TL;DR: Two humanized and Fc-silenced IgG antibodies generated have single-agent anti-tumor efficacy and combination synergy with anti-PD1 antibodies in mice and should be entering clinical trials by early 2022.
1321 A biparatopic anti-HER2 antibody enabled with conditional 4–1BB agonism induces potent anti-tumor efficacy
Liandi Chen,Weifeng Huang,Xiaoniu Miao,Shaogang Peng,Chao Wang,Yao Yan,Chuan-Chu Chou,Andy Tsun,Yi Luo +8 more
- 01 Nov 2022
TL;DR: PM1234 as mentioned in this paper is a trispecific antibody that binds to two different epitopes of HER2 (ECD4 and ECD2), and the CRD4 domain of 4-1BB.
Abstract 5554: A bispecific T cell engager targeting CEACAM5/6 exhibits strong anti-tumor efficacy in pre-clinical studies
TL;DR: A bispecific TCE with high selectivity to CEACAM5/6 overexpressing cancer cells was engineered and displays potent anti-tumor efficacy, and support from target selectivity testing shows promising safety traits.